MOVING TO THE SIDELINES: Oppenheimer analyst Chris Kotowski downgraded Morgan Stanley ($MS) to Perform from Outperform and removed his prior $112 price target on the shares, stating that the rating change is "based purely on valuation." While his forward estimates are largely unchanged, with the industry's strong showing in recent weeks his valuation model shows just 7% upside for Morgan Stanley shares. The bank stocks on his recommended list include Bank of America ($BAC), Citi ($C), Goldman Sachs ($GS), Jefferies Financial Group ($JEF) and U.S. Bancorp ($USB). BUY BOEING: Bernstein analyst Douglas Harned upgraded Boeing ($BA) to Outperform from Market Perform with a price target of $279, up from $252, on an increased traffic and capacity forecast as well as raised delivery outlook. The analyst believes "we are finally heading to the inflection point for global travel." The investment story "is not totally clean," but it is heading in the right direction, Harned tells investors in a research note. CAPPED UPSIDE: Cowen analyst Cai von Rumohr downgraded Lockheed Martin ($LMT) to Market Perform from Outperform with a price target of $375, down from $400. Though von Rumohr feels Lockheed Martin still offers well-supported peer-hi yields on its dividend and free cash flow, he argued that its relative upside looks capped by pared F-35 delivery plans, disappointing initial 2022 guidance, and other overhangs, the analyst told investors in a research note. UNIQUE CONCEPT: Deutsche Bank analyst Brian Mullan initiated coverage of Wingstop ($WING) with a Hold rating and $178 price target. Wingstop is a "very unique concept operating in the fastest-growing category within limited service restaurants," with share gains likely to continue, Mullan told investors in a research note. The analyst cited valuation for the Hold rating. EXPECTATIONS NOW RE-CALIBRATED: Citi analyst Andrew Baum upgraded Eli Lilly ($LLY) to Buy from Neutral with a price target of $265, up from $210. The analyst noted that the upgrade is "predominately valuation driven" following the 15% selloff in the shares. He believes Alzheimer's launch expectations are now re-calibrated and points out that his earnings estimates are 2%-20% above consensus. Baum also added that while he never believed in the "exuberant" initial market launch expectations for Biogen's Aduhelm, he remains optimistic for the pending outcome of Eli Lilly's TRAILBLAZER-ALZ2 data set expected in the first quarter of 2023 and long-term commercial success. And in the near-term, acceleration in Aduhelm adoption would aid Lilly's share price, Baum told investors in a research note.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .